News

Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase. The mathematical model developed in InSysBio, described how exactly such a non-standard composition will accumulate in various tissues of the body.

Read more...

Moscow, Russia - 21 June, 2017. InSysBio scientific group led by Tatiana Karelina developed a quantitative system pharmacology model of Alzheimer’s disease. First part published in CPT PSP shows how to design initial phases of clinical trials of new drugs and to interpret the data obtained.

Read more...

Moscow, Russia - May 23, 2017. InSysBio CEO Oleg Demin gives a talk at the 6th FIP Pharmaceutical Sciences World Congress2017. He will speak about how to use QSP modeling to investigate drug safety at different stages of development.

Read more...

Moscow, Russia – March 28, 2017. On the 1st April, Tatyana Karelina, ISBM leading specialist in neurodegenerative field, will present a poster entitled "Amyloid toxicity and different mechanisms of action for amyloid-targeted treatments studied by quantitative systems pharmacology model" at the 13th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders to be held on March 29 - April 2, Vienna, Austria. The research was made in collaboration with Timothy Nicholas, Pfizer. The aim of the presentation is to show how quantitative systems pharmacology (QSP) modeling helps to analyze modern Alzheimer’s disease therapies and hypotheses.

Read more...

Moscow, Russia – March 14th, 2017. Institute for Systems Biology Moscow – a company, providing modeling services for innovative drug design, announced participation in ASCPT 2017 Meeting, which is held on 15-18 March in Washington, DC. ISBM will present several studies and demonstrate an updated version of platform for quantitative systems pharmacology modeling of immune response - Immune Response Template.

Read more...

20-22 February 2017 the 10th ISBM Enclosed Conference was held. For ten years the employees annually have been meeting together to share their scientific results and talk over future plans. ISBM did a great job in this working year.

Read more...

Moscow, Russia - February 2, 2017. Institute for Systems Biology Moscow (ISBM) announced the recent update of the Immune Response Template (IRT) platform and its online demo. The project aimed to integrate and visualize available data on immune cells, cytokine, chemokines and other mediators interactions in human. IRT is a unique tool due to its focus on quantitative systems pharmacology (QSP) modeling. Using the platform modelers in pharmaceutical companies can strongly improve the drug R&D process.

Read more...

Moscow, Russia - December 20, 2016. Oleg Demin, CEO of the Institute for Systems Biology Moscow, gave a talk at the seminar "Big data and decision support systems for pharmaceuticals.".

The event held on December 19, Moscow was organized by the "National Technology Initiative" and the Semantic Hub company. The representatives of big Russian and international pharmaceutical companies, such as P-PHARM, Bayer and AstraZeneca, and developers of information technology attended the seminar. During the meeting, participants discussed the main trends and prospects of further cooperation.

Read more...

Moscow, Russia - November 29th, 2016. Institute for Systems Biology Moscow (www.insysbio.ru), one of the pioneers in bio-modeling and simulation announced the study made in collaboration with scientists of two pharmaceutical leaders: MedImmune and AstraZeneca. The research published in CPT Pharmacometrics & Systems Pharmacology shows how systems pharmacology modeling can help in validation of Asthma biomarkers for patients taking anti-interleukin medication.

Eosinophils (EOS) as a type of leukocytes are responsible for tissue inflammation under pathological conditions. For asthma EOS airway infiltration is a key feature. Historically high blood eosinophilic count is known to be a typical biomarker of asthma progression, though it may not correlate with amount of eosinophils in airways. Several new anti-asthmatic compounds either just appeared on the market or are at the late stage of development. These include emerging T-helper type 2 cytokine-based biotherapeutics such as tralokinumab, lebrikizumab (anti-interleukin-13) and mepolizumab (anti- interleukin-5). Clinical trials have shown that all these antibodies reduce asthma effects in airways except the fact of different EOS response. Using both tralokinumab and lebrikizumab leads to increase in blood eosinophils concentration in patients’ samples.

Read more...

Moscow, Russia - October 22nd, 2016. Institute for Systems Biology Moscow, a private research organization focused on application of quantitative system pharmacology (QSP) modeling to different stages of drug research and development, today announced their participation and poster presentation at ACoP7 to be held in Bellevue, WA on October 23-26, 2016.

Read more...